Developing personalized treatments for B-cell cancers using aptamers.
A Practical Approach to Tumor-Specific Aptamers for B-Cell Hematologic Malignancies
This study is exploring a new way to create personalized treatments for patients with certain blood cancers by finding special markers on their cancer cells, using a clever tool to develop tiny DNA or RNA strands that can target these markers, which could lead to better and faster ways to diagnose and treat their condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia Univ New York Morningside NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10834040 on NIH RePORTER |
What this research studies
This research focuses on creating personalized medicine approaches for patients with B-cell hematologic malignancies by targeting unique tumor-specific markers found on their cancer cells. The study utilizes a novel microfluidic platform called microSELEX to efficiently generate aptamers, which are short strands of DNA or RNA that can specifically bind to these tumor markers. By isolating these aptamers, the research aims to improve diagnostics and treatment strategies tailored to individual patients, enhancing the effectiveness of cancer care. This approach addresses the challenges of traditional methods that are often time-consuming and impractical for personalized applications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with B-cell hematologic malignancies, such as multiple myeloma or certain types of lymphomas.
Not a fit: Patients with non-B-cell malignancies or those who do not have identifiable tumor-specific markers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with B-cell cancers.
How similar studies have performed: Previous studies have shown promise in using patient-specific antibodies for similar applications, but this approach using aptamers is innovative and less tested.
Where this research is happening
New York, United States
- Columbia Univ New York Morningside — New York, United States (Active)
Researchers
- Principal investigator: Lin, Qiao — Columbia Univ New York Morningside
- Study coordinator: Lin, Qiao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.